Brainsway Ltd (BWAY) - Net Assets
Based on the latest financial reports, Brainsway Ltd (BWAY) has net assets worth $75.80 Million USD as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($117.00 Million) and total liabilities ($41.20 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore how large is Brainsway Ltd's balance sheet for the complete picture of this company's asset base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $75.80 Million |
| % of Total Assets | 64.78% |
| Annual Growth Rate | 2.21% |
| 5-Year Change | 27.73% |
| 10-Year Change | 611.78% |
| Growth Volatility | 87.58 |
Brainsway Ltd - Net Assets Trend (2000–2025)
This chart illustrates how Brainsway Ltd's net assets have evolved over time, based on quarterly financial data. Check BWAY tangible net worth ratio to evaluate the tangible quality of the company's equity base.
Annual Net Assets for Brainsway Ltd (2000–2025)
The table below shows the annual net assets of Brainsway Ltd from 2000 to 2025. For live valuation and market cap data, see BWAY stock market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $73.22 Million | +17.51% |
| 2024-12-31 | $62.31 Million | +49.86% |
| 2023-12-31 | $41.58 Million | -8.41% |
| 2022-12-31 | $45.40 Million | -20.81% |
| 2021-12-31 | $57.33 Million | +191.97% |
| 2020-12-31 | $19.63 Million | -18.93% |
| 2019-12-31 | $24.22 Million | +248.39% |
| 2018-12-31 | $6.95 Million | -45.35% |
| 2017-12-31 | $12.72 Million | +23.66% |
| 2016-12-31 | $10.29 Million | -20.22% |
| 2015-12-31 | $12.89 Million | -17.22% |
| 2014-12-31 | $15.58 Million | +6.32% |
| 2013-12-31 | $14.65 Million | +85.09% |
| 2012-12-31 | $7.92 Million | -81.33% |
| 2000-12-31 | $42.39 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Brainsway Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 9074800000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $430.00K | 0.59% |
| Other Comprehensive Income | $-2.19 Million | -2.99% |
| Other Components | $165.73 Million | 226.34% |
| Total Equity | $73.22 Million | 100.00% |
Brainsway Ltd Competitors by Market Cap
The table below lists competitors of Brainsway Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Medprin Regenerative Medical Technologies Co. Ltd.
SHE:301033
|
$604.39 Million |
|
Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd.
SHE:301096
|
$604.50 Million |
|
CSB Bank Limited
NSE:CSBBANK
|
$604.65 Million |
|
Gladstone Commercial Corporation
NASDAQ:GOOD
|
$605.09 Million |
|
SZZT Electronics Co Ltd
SHE:002197
|
$604.13 Million |
|
Bright Minds Biosciences Inc
NASDAQ:DRUG
|
$604.13 Million |
|
Selamat Sempurna Tbk
JK:SMSM
|
$604.01 Million |
|
China Fortune Land Development Co Ltd
SHG:600340
|
$603.90 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Brainsway Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 62,313,000 to 73,221,000, a change of 10,908,000 (17.5%).
- Net income of 7,633,000 contributed positively to equity growth.
- Other factors increased equity by 3,275,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $7.63 Million | +10.42% |
| Other Changes | $3.27 Million | +4.47% |
| Total Change | $- | 17.51% |
Book Value vs Market Value Analysis
This analysis compares Brainsway Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 4.41x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 37.84x to 4.41x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2012-12-31 | $0.40 | $15.23 | x |
| 2013-12-31 | $0.61 | $15.23 | x |
| 2014-12-31 | $1.09 | $15.23 | x |
| 2015-12-31 | $0.89 | $15.23 | x |
| 2016-12-31 | $0.71 | $15.23 | x |
| 2017-12-31 | $1.72 | $15.23 | x |
| 2018-12-31 | $0.42 | $15.23 | x |
| 2019-12-31 | $2.36 | $15.23 | x |
| 2020-12-31 | $0.87 | $15.23 | x |
| 2021-12-31 | $1.84 | $15.23 | x |
| 2022-12-31 | $1.38 | $15.23 | x |
| 2023-12-31 | $1.25 | $15.23 | x |
| 2024-12-31 | $1.79 | $15.23 | x |
| 2025-12-31 | $3.45 | $15.23 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Brainsway Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 10.42%
- The company shows good efficiency in utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 14.62%
- • Asset Turnover: 0.46x
- • Equity Multiplier: 1.54x
- Recent ROE (10.42%) is above the historical average (-40.23%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2012 | -120.79% | -1624.27% | 0.03x | 2.18x | $-6.41 Million |
| 2013 | -91.00% | -598.99% | 0.07x | 2.28x | $-7.90 Million |
| 2014 | -42.02% | -193.64% | 0.13x | 1.65x | $-8.10 Million |
| 2015 | -31.69% | -60.10% | 0.31x | 1.72x | $-5.38 Million |
| 2016 | -23.30% | -20.80% | 0.58x | 1.94x | $-3.43 Million |
| 2017 | -55.45% | -63.29% | 0.41x | 2.12x | $-8.33 Million |
| 2018 | -93.20% | -39.51% | 0.69x | 3.39x | $-7.17 Million |
| 2019 | -42.64% | -44.71% | 0.60x | 1.60x | $-12.75 Million |
| 2020 | -27.43% | -24.41% | 0.65x | 1.73x | $-7.35 Million |
| 2021 | -11.27% | -21.79% | 0.39x | 1.32x | $-12.19 Million |
| 2022 | -29.41% | -49.12% | 0.42x | 1.42x | $-17.89 Million |
| 2023 | -10.09% | -13.20% | 0.50x | 1.51x | $-8.36 Million |
| 2024 | 4.69% | 7.12% | 0.43x | 1.51x | $-3.31 Million |
| 2025 | 10.42% | 14.62% | 0.46x | 1.54x | $310.90K |
Industry Comparison
This section compares Brainsway Ltd's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $411,255,254
- Average return on equity (ROE) among peers: -85.10%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Brainsway Ltd (BWAY) | $75.80 Million | -120.79% | 0.54x | $604.35 Million |
| Abbott Laboratories (ABT) | $3.67 Billion | 38.07% | 1.09x | $183.80 Billion |
| Adagio Medical Holdings, Inc Common Stock (ADGM) | $-72.62 Million | 0.00% | 0.00x | $8.40 Million |
| Aethlon Medical Inc (AEMD) | $1.50 Million | -324.29% | 0.70x | $867.97K |
| Acutus Medical Inc (AFIB) | $126.58 Million | -80.56% | 0.52x | $903.35K |
| Adapthealth Corp (AHCO) | $280.85 Million | -57.55% | 5.46x | $1.39 Billion |
| 20/20 Biolabs, Inc. Common Stock (AIDX) | $2.15 Million | -112.84% | 0.45x | $4.45 Million |
| Allurion Technologies, Inc. (ALUR) | $-34.28 Million | 0.00% | 0.00x | $13.77 Million |
| Autonomix Medical, Inc. Common Stock (AMIX) | $5.89 Million | -283.55% | 0.29x | $1.87 Million |
| Artivion Inc (AORT) | $121.54 Million | 6.06% | 0.22x | $1.16 Billion |
| Apyx Medical Inc (APYX) | $6.01 Million | -36.31% | 0.22x | $171.68 Million |
About Brainsway Ltd
BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious and late-life depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post-traumatic stress disorders, … Read more